257 related articles for article (PubMed ID: 9308751)
1. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
[TBL] [Abstract][Full Text] [Related]
2. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Favaloro EJ; Mirochnik O; McDonald D
Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
[TBL] [Abstract][Full Text] [Related]
3. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
[TBL] [Abstract][Full Text] [Related]
4. Congenital resistance to activated protein C in patients with lupus anticoagulants: evaluation of two functional assays.
Galli M; Duca F; Ruggeri L; Finazzi G; Negri B; Moia M
Thromb Haemost; 1998 Aug; 80(2):246-9. PubMed ID: 9716147
[TBL] [Abstract][Full Text] [Related]
5. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
Pereira J; Quiroga T; Goycoolea M; Muñoz B; Hidalgo P; Kaltwasser G; Mezzano D
Rev Med Chil; 1996 Jun; 124(6):663-8. PubMed ID: 9041721
[TBL] [Abstract][Full Text] [Related]
6. The effect of lupus anticoagulant in the second-generation assay for activated protein C resistance.
Ragland BD; Reed CE; Eiland BM; Tichenor PH; Hudson CL; Fritsma GA; Adler BK; Marques MB
Am J Clin Pathol; 2003 Jan; 119(1):66-71. PubMed ID: 12520699
[TBL] [Abstract][Full Text] [Related]
7. Laboratory diagnosis of hereditary thrombophilia.
Michiels JJ; Hamulyák K
Semin Thromb Hemost; 1998; 24(4):309-20. PubMed ID: 9763348
[TBL] [Abstract][Full Text] [Related]
8. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
[TBL] [Abstract][Full Text] [Related]
9. Activated protein C resistance assay as a screening test for thromboembolic disposition.
Shizuka R; Amagai H; Kojima J; Fukumura Y; Kanda T; Kobayashi I
J Med; 1997; 28(5-6):381-6. PubMed ID: 9604796
[TBL] [Abstract][Full Text] [Related]
10. A prothrombinase-based assay for detection of resistance to activated protein C.
Nicolaes GA; Thomassen MC; van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
Thromb Haemost; 1996 Sep; 76(3):404-10. PubMed ID: 8883278
[TBL] [Abstract][Full Text] [Related]
11. Activated protein C resistance assay performance: improvement by sample dilution with factor V-deficient plasma.
Strobl FJ; Hoffman S; Huber S; Williams EC; Voelkerding KV
Arch Pathol Lab Med; 1998 May; 122(5):430-3. PubMed ID: 9593344
[TBL] [Abstract][Full Text] [Related]
12. Proposal for objective evaluation of the performance of various functional APC-resistance tests in genotyped patients.
Freyburger G; Javorschi S; Labrouche S; Bernard P
Thromb Haemost; 1997 Nov; 78(5):1360-5. PubMed ID: 9408020
[TBL] [Abstract][Full Text] [Related]
13. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. The APC Resistance Study Group.
Rosén S; Johansson K; Lindberg K; Dahlbäck B
Thromb Haemost; 1994 Aug; 72(2):255-60. PubMed ID: 7831662
[TBL] [Abstract][Full Text] [Related]
14. A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
De Bel AV; Van der Cruyssen GA; Devreese KM
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):155-60. PubMed ID: 16479199
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
Svensson PJ; Zöller B; Dahlbäck B
Thromb Haemost; 1997 Feb; 77(2):332-5. PubMed ID: 9157592
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of sensitivity and specificity of confirmatory assays for lupus anticoagulant (LA) detection].
Imoto K; Yasumuro Y; Taki M; Suzuki Y; Akatu S; Tajima C; Ichikawa Y
Rinsho Byori; 1996 Aug; 44(8):797-801. PubMed ID: 8816068
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S.
D'Angelo SV; Gilardoni F; D'Angelo A
Thromb Haemost; 1989 Nov; 62(3):861-7. PubMed ID: 2531939
[TBL] [Abstract][Full Text] [Related]
18. Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis.
Tripodi A; Negri B; Bertina RM; Mannucci PM
Thromb Haemost; 1997 Mar; 77(3):436-9. PubMed ID: 9065989
[TBL] [Abstract][Full Text] [Related]
19. [Activated protein C resistance as a cause of thrombophilia].
Ruiz-Argüelles GJ
Rev Invest Clin; 1996; 48(3):223-9. PubMed ID: 8966383
[TBL] [Abstract][Full Text] [Related]
20. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
Montes MA; Fox EA; Longtine JA; Dorfman DM
Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
